Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

RDM researchers tested the method in COVID-19 patients, to find that the results predicted in-hospital mortality.

Photo composite showing a comparison of Peri-imap pvat images at baseline, and after covid infection. The delineation in the covid image is much less clear.

 

Cardiovascular complications have emerged as a key feature of COVID-19. Now, a group of RDM researchers have found a new way of directly quantifying vascular inflammation in COVID-19 patients. The study, published in Lancet Digital Health,  could pave the way to more efficient trials of new treatments and identify patients who might be at risk of long-term complications. 

Professor Charalambos Antoniades, BHF Chair of Cardiovascular Medicine at the Radcliffe Department of Medicine, and lead author of the study, said ”We’ve developed a novel image analysis platform, which uses artificial intelligence to quantify cytokine-driven vascular inflammation from routine CT angiograms.” CT angiograms combine a CT scan with an injection of a special dye to produce pictures of blood vessels and tissue structure in the heart, and are relatively non-invasive and routinely done in many hospitals. 

Professor Antoniades and his team used the data from CT angiograms to carry out ‘virtual biopsies’, by deriving a radiomic ‘signature’ from the angiogram images, and then using machine learning to train this signature against transcriptomic profiles (derived from RNA sequencing data) from tissue biopsies.  This is therefore the first study to introduce a new radiotranscriptomics analysis pipeline., 

Using this method, the researchers developed C19-RS, a radiotranscriptomic signature of vascular cytokine-driven arterial inflammation.  

The team tested this new radiotranscriptomic signature with data from routine CT angiograms of patients with COVID-19, to find that cytokine-driven vascular inflammation predicts thrombosis and the likelihood of patients dying in hospital. This method also identified patients who respond well to steroid treatment. 

Dr Christos Kotanidis, the first author of the paper, said “Quantifying cytokine-induced vascular inflammation in patients with COVID-19 can therefore help clinicians in risk stratification, and potentially guide the deployment of specific anti-inflammatory treatments to those who need them.”  

 The new radiotranscriptomics platform also allows the development of customised imaging biomarkers of vascular inflammation, tailored to the type of vascular inflammation of interest to clinicians and researchers, and the changes that it causes to the perivascular space around human arteries. The research team therefore think that the method could also be used for other vascular inflammatory diseases (such as aortic aneurysms, carotid artery disease, or even autoimmune diseases like temporal arteritis), following appropriate independent validation and cost-effectiveness analyses. 

 This study was funded by the Engineering and Physical Sciences Research Council, British Heart Foundation, Oxford BHF Centre of Research Excellence, Innovate UK, NIHR Oxford Biomedical Research Centre and the Wellcome Trust. 

Read the full paper in Lancet Digital Health. 

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

Professor Hugh Watkins wins £30 million research award to cure killer heart diseases

The British Heart Foundation award aims to help researchers rewrite DNA, in “defining moment” for cardiovascular medicine.

Novel all-in-one vaccine developed to tackle future coronavirus threats

Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.